Wellington Management Group LLP Sells 1,309,593 Shares of Moderna, Inc. (NASDAQ:MRNA)

Wellington Management Group LLP lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 25.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,915,092 shares of the company’s stock after selling 1,309,593 shares during the quarter. Wellington Management Group LLP’s holdings in Moderna were worth $162,790,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of MRNA. Cerity Partners LLC grew its stake in shares of Moderna by 7.0% during the 3rd quarter. Cerity Partners LLC now owns 13,769 shares of the company’s stock worth $920,000 after acquiring an additional 900 shares during the period. Quantbot Technologies LP purchased a new stake in Moderna during the third quarter valued at about $150,000. Townsquare Capital LLC boosted its position in Moderna by 42.7% during the third quarter. Townsquare Capital LLC now owns 5,288 shares of the company’s stock worth $353,000 after purchasing an additional 1,583 shares during the period. Public Sector Pension Investment Board increased its stake in shares of Moderna by 18.0% in the third quarter. Public Sector Pension Investment Board now owns 16,380 shares of the company’s stock worth $1,095,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Benjamin Edwards Inc. raised its position in shares of Moderna by 14,009.7% in the third quarter. Benjamin Edwards Inc. now owns 4,374 shares of the company’s stock valued at $292,000 after purchasing an additional 4,343 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on MRNA shares. Bank of America reduced their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. Argus cut Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. dropped their price objective on Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Friday, March 21st. Morgan Stanley cut their target price on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Finally, Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $59.00.

Moderna Trading Up 2.1 %

MRNA opened at $27.72 on Thursday. The stock has a market capitalization of $10.72 billion, a P/E ratio of -2.99 and a beta of 1.86. The stock has a 50-day moving average price of $34.21 and a 200-day moving average price of $43.44. Moderna, Inc. has a 12-month low of $26.26 and a 12-month high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.